- Val-Cit-PAB-MMAE
-
- $50.00
-
2026-07-16
- CAS:644981-35-1
- Purity: 99.66%
- Supply Ability: 10g
- Val-Cit-PAB-MMAE
-
-
2025-06-07
- CAS:644981-35-1
- Min. Order: 100mg
- Purity: >98.00%
- Supply Ability: 100mg
|
| | Val-Cit-PAB-MMAE Basic information |
| Product Name: | Val-Cit-PAB-MMAE | | Synonyms: | Val-Cit-PAB-MMAE;4H-1-Benzopyran-4-one,7-hydroxy-4-(trifluoromethyl)-;Drug-Linker Conjugates for ADC,inhibit,Inhibitor,Val Cit PAB MMAE,ValCitPABMMAE;4-((S)-2-((S)-2-Amino-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate;VCPMMAE;Val-Cit-PAB-MMAE, 10 mM in DMSO;N-Methyl-N-[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide | | CAS: | 644981-35-1 | | MF: | C58H94N10O12 | | MW: | 1123.43 | | EINECS: | | | Product Categories: | ADCs;ADC LINKER | | Mol File: | 644981-35-1.mol |  |
| | Val-Cit-PAB-MMAE Chemical Properties |
| Boiling point | 1211.860±65.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.174±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | storage temp. | -20°C | | solubility | Soluble in DCM | | form | Solid | | pka | 13.665±0.20(predicted) | | color | White to off-white | | InChIKey | WZEAGSMYTVSXQA-DQTLHWFHNA-N |
| | Val-Cit-PAB-MMAE Usage And Synthesis |
| Description | Val-Cit-PAB-MMAE is a precursor of antibody drug conjugate. It contains a a protease-sensitive Val-Cit dipeptide, and a MMAE payload. The MMAE is a synthetic antineoplastic agent. It can be attached to a monoclonal antibody (MAB) which directs it toward cancer cells. | | Uses | Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization. | | IC 50 | Auristatin | | References | [1] Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897. DOI:10.1158/1078-0432.CCR-09-2069 |
| | Val-Cit-PAB-MMAE Preparation Products And Raw materials |
|